• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk factors associated with major cerebrovascular complications after intracranial stenting.颅内支架置入术后主要脑血管并发症的相关危险因素。
Neurology. 2009 Jun 9;72(23):2014-9. doi: 10.1212/01.wnl.0b013e3181a1863c. Epub 2009 Mar 18.
2
The learning curve for neuroendovascular procedures: how important is it?神经血管介入手术的学习曲线:其重要性如何?
Neurology. 2009 Jun 9;72(23):1974-5. doi: 10.1212/WNL.0b013e3181a92c6f. Epub 2009 Apr 29.
3
Effect of Stenting Plus Medical Therapy vs Medical Therapy Alone on Risk of Stroke and Death in Patients With Symptomatic Intracranial Stenosis: The CASSISS Randomized Clinical Trial.支架置入联合药物治疗与单纯药物治疗对症状性颅内狭窄患者卒中和死亡风险的影响:CASSISS 随机临床试验。
JAMA. 2022 Aug 9;328(6):534-542. doi: 10.1001/jama.2022.12000.
4
Does the Stenting Versus Aggressive Medical Therapy Trial Support Stenting for Subgroups With Intracranial Stenosis?支架置入术与强化药物治疗试验是否支持对颅内狭窄亚组进行支架置入?
Stroke. 2015 Nov;46(11):3282-4. doi: 10.1161/STROKEAHA.115.009846. Epub 2015 Sep 17.
5
Do patients with basilar or vertebral artery stenosis have a higher stroke incidence poststenting?基底动脉或椎动脉狭窄患者支架置入术后卒中发生率更高吗?
J Neurointerv Surg. 2010 Mar;2(1):50-4. doi: 10.1136/jnis.2009.000356. Epub 2009 Dec 4.
6
Transcarotid artery revascularization versus transfemoral carotid artery stenting in the Society for Vascular Surgery Vascular Quality Initiative.血管外科学会血管质量倡议中的经颈动脉动脉血运重建与经股颈动脉血管成形术。
J Vasc Surg. 2019 Jan;69(1):92-103.e2. doi: 10.1016/j.jvs.2018.05.011. Epub 2018 Jun 22.
7
Impact of qualifying artery on the efficacy of stenting plus medical therapy versus medical therapy alone in patients with symptomatic intracranial stenosis: a post-hoc analysis of the CASSISS trial.症状性颅内狭窄患者支架置入联合药物治疗与单纯药物治疗疗效的影响因素:CASSISS 试验的事后分析。
J Neurointerv Surg. 2024 Jun 17;16(7):663-669. doi: 10.1136/jnis-2023-020456.
8
Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial.症状性椎动脉狭窄患者的支架置入与药物治疗:一项随机开放标签 2 期试验。
Lancet Neurol. 2015 Jun;14(6):606-14. doi: 10.1016/S1474-4422(15)00017-4. Epub 2015 Apr 20.
9
Factors Associated With Recurrent Ischemic Stroke in the Medical Group of the SAMMPRIS Trial.SAMMPRIS试验医疗组中复发性缺血性卒中的相关因素。
JAMA Neurol. 2016 Mar;73(3):308-15. doi: 10.1001/jamaneurol.2015.4315.
10
Stenting for symptomatic intracranial arterial stenosis in China: 1-year outcome of a multicentre registry study.中国症状性颅内动脉狭窄血管内治疗:一项多中心注册研究的 1 年结果。
Stroke Vasc Neurol. 2018 May 7;3(3):176-184. doi: 10.1136/svn-2017-000137. eCollection 2018 Sep.

引用本文的文献

1
Endovascular therapy vs. conventional medical treatment for symptomatic intracranial atherosclerotic stenosis: an updated meta-analysis of randomized controlled trials.血管内治疗与传统药物治疗对症状性颅内动脉粥样硬化狭窄的疗效比较:随机对照试验的最新荟萃分析
Neuroradiology. 2025 Aug 20. doi: 10.1007/s00234-025-03736-5.
2
Intracranial stenting compared to medical treatment alone for intracranial atherosclerosis patients: An updated meta-analysis.颅内动脉粥样硬化患者颅内支架置入术与单纯药物治疗的比较:一项更新的荟萃分析。
J Cerebrovasc Endovasc Neurosurg. 2024 Jun;26(2):152-162. doi: 10.7461/jcen.2023.E2023.03.002. Epub 2023 Nov 29.
3
Percutaneous transluminal angioplasty and stenting vs aggressive medical management on stroke or intracranial atherosclerotic stenosis: a systematic review and meta-analysis.经皮腔内血管成形术和支架置入与强化药物治疗对卒中和颅内动脉粥样硬化性狭窄的影响:系统评价和荟萃分析。
Sci Rep. 2023 May 9;13(1):7567. doi: 10.1038/s41598-023-34663-1.
4
Effect of Stenting Plus Medical Therapy vs Medical Therapy Alone on Risk of Stroke and Death in Patients With Symptomatic Intracranial Stenosis: The CASSISS Randomized Clinical Trial.支架置入联合药物治疗与单纯药物治疗对症状性颅内狭窄患者卒中和死亡风险的影响:CASSISS 随机临床试验。
JAMA. 2022 Aug 9;328(6):534-542. doi: 10.1001/jama.2022.12000.
5
The effectiveness of enterprise stent use on the treatment of intracranial atherosclerosis disease.企业支架在颅内动脉粥样硬化疾病治疗中的有效性。
Neuroradiol J. 2022 Oct;35(5):612-618. doi: 10.1177/19714009221083143. Epub 2022 Apr 7.
6
Current status and outlook of biodegradable metals in neuroscience and their potential applications as cerebral vascular stent materials.生物可降解金属在神经科学中的现状与展望及其作为脑血管支架材料的潜在应用
Bioact Mater. 2021 Oct 11;11:140-153. doi: 10.1016/j.bioactmat.2021.09.025. eCollection 2022 May.
7
Acute intracranial stenting with mechanical thrombectomy is safe and efficacious in patients diagnosed with underlying intracranial atherosclerotic disease.对于诊断为颅内动脉粥样硬化性疾病的患者,急性颅内支架取栓术联合机械血栓切除术是安全且有效的。
Interv Neuroradiol. 2022 Aug;28(4):419-425. doi: 10.1177/15910199211039403. Epub 2021 Sep 13.
8
Timing and Outcomes of Intracranial Stenting in the Post-SAMMPRIS Era: A Systematic Review.SAMMPRIS 时代后颅内支架置入的时机与结局:一项系统评价
Front Neurol. 2021 Feb 4;12:637632. doi: 10.3389/fneur.2021.637632. eCollection 2021.
9
Update in the treatment of intracranial atherosclerotic disease.颅内动脉粥样硬化性疾病治疗的新进展。
Stroke Vasc Neurol. 2019 Oct 16;5(1):59-64. doi: 10.1136/svn-2019-000279. eCollection 2020.
10
Intracranial Stenting: Is It Still an Option for Treatment of Patients With Intracranial Atherosclerosis?颅内支架置入术:它仍是颅内动脉粥样硬化患者的一种治疗选择吗?
Front Neurol. 2019 Nov 22;10:1248. doi: 10.3389/fneur.2019.01248. eCollection 2019.

本文引用的文献

1
The NIH registry on use of the Wingspan stent for symptomatic 70-99% intracranial arterial stenosis.美国国立卫生研究院关于使用Wingspan支架治疗症状性颅内动脉狭窄70%-99%的登记研究。
Neurology. 2008 Apr 22;70(17):1518-24. doi: 10.1212/01.wnl.0000306308.08229.a3. Epub 2008 Jan 30.
2
Intracranial arterial stenting for symptomatic stenoses: a Latin American experience.症状性颅内动脉狭窄的颅内动脉支架置入术:拉丁美洲的经验
Surg Neurol. 2007 Oct;68(4):378-86. doi: 10.1016/j.surneu.2006.11.062.
3
Long-term outcome of elective stenting for symptomatic intracranial vertebrobasilar stenosis.症状性颅内椎基底动脉狭窄择期支架置入术的长期疗效
Neurology. 2007 Mar 13;68(11):856-8. doi: 10.1212/01.wnl.0000256713.23864.be.
4
Primary stent therapy for symptomatic intracranial atherosclerotic stenosis: 1-year follow-up angiographic and midterm clinical outcomes.症状性颅内动脉粥样硬化狭窄的初次支架治疗:1年随访血管造影及中期临床结果
J Neurosurg. 2006 Aug;105(2):235-41. doi: 10.3171/jns.2006.105.2.235.
5
Appropriateness of learning curve for carotid artery stenting: an analysis of periprocedural complications.颈动脉支架置入术学习曲线的适宜性:围手术期并发症分析
J Vasc Surg. 2006 Dec;44(6):1205-11; discussion 1211-2. doi: 10.1016/j.jvs.2006.08.027. Epub 2006 Oct 20.
6
Perforator stroke after elective stenting of symptomatic intracranial stenosis.症状性颅内狭窄择期支架置入术后的穿支动脉卒中
Neurology. 2006 Jun 27;66(12):1868-72. doi: 10.1212/01.wnl.0000219744.06992.bb.
7
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.有症状的颅内动脉狭窄区域缺血性卒中的预测因素。
Circulation. 2006 Jan 31;113(4):555-63. doi: 10.1161/CIRCULATIONAHA.105.578229. Epub 2006 Jan 23.
8
Carotid artery stenting with neuroprotection: assessing the learning curve and treatment outcome.带神经保护装置的颈动脉支架置入术:评估学习曲线和治疗结果。
Am J Surg. 2005 Dec;190(6):850-7. doi: 10.1016/j.amjsurg.2005.08.008.
9
Endovascular reconstruction by means of stent placement in symptomatic intracranial atherosclerotic stenosis.通过支架置入术对有症状的颅内动脉粥样硬化性狭窄进行血管内重建。
Neurol Res. 2005;27 Suppl 1:S84-8. doi: 10.1179/016164105X35495.
10
Stent-assisted angioplasty of symptomatic intracranial vertebrobasilar artery stenosis: feasibility and follow-up results.症状性颅内椎基底动脉狭窄的支架辅助血管成形术:可行性及随访结果
AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1381-8.

颅内支架置入术后主要脑血管并发症的相关危险因素。

Risk factors associated with major cerebrovascular complications after intracranial stenting.

作者信息

Nahab F, Lynn M J, Kasner S E, Alexander M J, Klucznik R, Zaidat O O, Chaloupka J, Lutsep H, Barnwell S, Mawad M, Lane B, Chimowitz M I

机构信息

Emory University, Atlanta, GA, USA.

出版信息

Neurology. 2009 Jun 9;72(23):2014-9. doi: 10.1212/01.wnl.0b013e3181a1863c. Epub 2009 Mar 18.

DOI:10.1212/01.wnl.0b013e3181a1863c
PMID:19299309
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2837590/
Abstract

BACKGROUND

There are limited data on the relationship between patient and site characteristics and clinical outcomes after intracranial stenting.

METHODS

We performed a multivariable analysis that correlated patient and site characteristics with the occurrence of the primary endpoint (any stroke or death within 30 days of stenting or stroke in the territory of the stented artery beyond 30 days) in 160 patients enrolled in this stenting registry. All patients presented with an ischemic stroke, TIA, or other cerebral ischemic event (e.g., vertebrobasilar insufficiency) in the territory of a suspected 50-99% stenosis of a major intracranial artery while on antithrombotic therapy.

RESULTS

Cerebral angiography confirmed that 99% (158/160) of patients had a 50-99% stenosis. In multivariable analysis, the primary endpoint was associated with posterior circulation stenosis (vs anterior circulation) (hazard ratio [HR] 3.4, 95% confidence interval [CI] 1.2-9.3, p = 0.018), stenting at low enrollment sites (< 10 patients each) (vs high enrollment site) (HR 2.8, 95% CI 1.1-7.6, p = 0.038), < or = 10 days from qualifying event to stenting (vs > or = 10 days) (HR 2.7, 95% CI 1.0-7.8, p = 0.058), and stroke as a qualifying event (vs TIA/other) (HR 3.2, 95% CI 0.9-11.2, p = 0.064). There was no significant difference in the primary endpoint based on age, gender, race, or percent stenosis (50-69% vs 70-99%).

CONCLUSIONS

Major cerebrovascular complications after intracranial stenting may be associated with posterior circulation stenosis, low volume sites, stenting soon after a qualifying event, and stroke as the qualifying event. These factors will need to be monitored in future trials of intracranial stenting.

摘要

背景

关于颅内支架置入术后患者及部位特征与临床结局之间的关系,相关数据有限。

方法

我们进行了一项多变量分析,将160例纳入该支架置入登记研究的患者的患者及部位特征与主要终点事件(支架置入后30天内发生任何卒中或死亡,或30天后支架置入动脉供血区域发生卒中)的发生情况进行关联分析。所有患者在接受抗栓治疗时,在主要颅内动脉疑似50% - 99%狭窄区域出现缺血性卒中、短暂性脑缺血发作(TIA)或其他脑缺血事件(如椎基底动脉供血不足)。

结果

脑血管造影证实99%(158/160)的患者存在50% - 99%的狭窄。在多变量分析中,主要终点事件与后循环狭窄(对比前循环)(风险比[HR] 3.4,95%置信区间[CI] 1.2 - 9.3,p = 0.018)、低入组量部位(每个部位<10例患者)的支架置入(对比高入组量部位)(HR 2.8,95% CI 1.1 - 7.6,p = 0.038)、从符合条件事件至支架置入≤10天(对比≥10天)(HR 2.7,95% CI 1.0 - 7.8,p = 0.058)以及卒中作为符合条件事件(对比TIA/其他)(HR 3.2,95% CI 0.9 - 11.2,p = 0.064)相关。基于年龄、性别、种族或狭窄百分比(50% - 69%对比70% - 99%),主要终点事件无显著差异。

结论

颅内支架置入术后的主要脑血管并发症可能与后循环狭窄、低入组量部位、符合条件事件后不久进行支架置入以及卒中作为符合条件事件有关。在未来的颅内支架置入试验中需要对这些因素进行监测。